Nu Skin sees 2025 EPS ex-Mavely gain 90c-$1.30, consensus 76c

Sees 2025 revenue $1.48B-$1.62B, consensus $1.7B. The company said, “We are encouraged by our recent progress in strengthening our business by driving sequential growth in our core Nu Skin (NUS) business, improving operational efficiencies and delivering strong cash flow. As we look ahead to 2025, our annual revenue guidance is $1.48 to $1.62 billion, with an approximate 3% foreign currency headwind. We anticipate reported EPS of $3.45 to $3.85 and growth in our adjusted EPS, which we estimate to be $0.90 to $1.30, excluding the gain from the sale of Mavely. For the first quarter, which is typically our lowest quarter due to seasonality of our business, we project revenue of $345 to $365 million. This assumes a negative foreign currency impact of approximately 3%, with reported earnings per share of $2.65 to $2.75 or $0.10 to $0.20, excluding the gain from the sale of Mavely. As we’ve executed on our restructuring plan and improved our cost structure, we are better positioned to execute our strategy and drive earnings growth in 2025.”